GlobeNewswire: ObsEva SA Contains the last 10 of 300 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T14:07:55ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/19/2848274/0/en/ObsEva-Announces-Update-on-Board-of-Directors.html?f=22&fvtc=4&fvtv=29937ObsEva Announces Update on Board of Directors2024-03-19T06:00:00Z<![CDATA[Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange]]>https://www.globenewswire.com/news-release/2024/02/28/2836594/0/en/ObsEva-Announces-Wind-Down-of-Operations-and-Notifies-SIX-that-it-Will-Lack-the-Resources-to-Establish-Audited-IFRS-Financial-Statements-for-2023.html?f=22&fvtc=4&fvtv=29937ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 20232024-02-28T06:00:00Z<![CDATA[Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange]]>https://www.globenewswire.com/news-release/2024/01/31/2820701/0/en/Geneva-Court-Grants-Temporary-Moratorium-to-ObsEva.html?f=22&fvtc=4&fvtv=29937Geneva Court Grants Temporary Moratorium to ObsEva2024-01-31T06:00:00Z<![CDATA[Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange]]>https://www.globenewswire.com/news-release/2023/11/30/2788224/0/en/ObsEva-Announces-Application-for-a-Moratorium-to-Facilitate-Pivotal-Deals.html?f=22&fvtc=4&fvtv=29937ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals2023-11-30T06:00:00Z<![CDATA[Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange]]>https://www.globenewswire.com/news-release/2023/10/27/2768722/0/en/Organon-Returns-Ebopiprant-to-XOMA.html?f=22&fvtc=4&fvtv=29937Organon Returns Ebopiprant to XOMA2023-10-27T21:00:00Z<![CDATA[Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange]]>https://www.globenewswire.com/news-release/2023/09/27/2750031/0/en/ObsEva-Files-half-Year-2023-Financial-Statements.html?f=22&fvtc=4&fvtv=29937ObsEva Files half Year 2023 Financial Statements2023-09-27T05:00:00Z<![CDATA[ObsEva Files half Year 2023 Financial Statements]]>https://www.globenewswire.com/news-release/2023/07/13/2704038/0/en/ObsEva-Recovers-Full-Worldwide-Rights-on-Nolasiban.html?f=22&fvtc=4&fvtv=29937ObsEva Recovers Full Worldwide Rights on Nolasiban2023-07-13T05:00:00Z<![CDATA[Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange]]>https://www.globenewswire.com/news-release/2023/06/30/2697507/0/en/ObsEva-SA-Announces-that-Shareholders-Approved-all-Board-Proposals-at-its-2023-Annual-General-Meeting-held-on-June-29-2023.html?f=22&fvtc=4&fvtv=29937ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2023 Annual General Meeting held on June 29, 20232023-06-30T05:00:00Z<![CDATA[Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange]]>https://www.globenewswire.com/news-release/2023/06/08/2684401/0/en/Annual-General-Meeting-2023.html?f=22&fvtc=4&fvtv=29937Annual General Meeting 20232023-06-08T05:00:00Z<![CDATA[Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange]]>https://www.globenewswire.com/news-release/2023/05/02/2658738/0/en/ObsEva-Appoints-Fabien-de-Ladonchamps-as-Chief-Executive-Officer.html?f=22&fvtc=4&fvtv=29937ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer2023-05-02T05:00:00Z<![CDATA[Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange]]>